- Home
- DSGN vs KULR Comparison
DSGN vs KULR Comparison
Compare DSGN & KULR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSGN
- KULR
- Stock Information
- Founded
- DSGN 2017
- KULR 2013
- Country
- DSGN United States
- KULR United States
- Employees
- DSGN N/A
- KULR N/A
- Industry
- DSGN Biotechnology: Pharmaceutical Preparations
- KULR Electrical Products
- Sector
- DSGN Health Care
- KULR Technology
- Exchange
- DSGN Nasdaq
- KULR Nasdaq
- Market Cap
- DSGN 208.9M
- KULR 241.0M
- IPO Year
- DSGN 2021
- KULR N/A
- Fundamental
- Price
- DSGN $3.87
- KULR $5.50
- Analyst Decision
- DSGN Hold
- KULR Strong Buy
- Analyst Count
- DSGN 1
- KULR 2
- Target Price
- DSGN $4.00
- KULR $40.00
- AVG Volume (30 Days)
- DSGN 92.9K
- KULR 2.6M
- Earning Date
- DSGN 08-12-2025
- KULR 08-11-2025
- Dividend Yield
- DSGN N/A
- KULR N/A
- EPS Growth
- DSGN N/A
- KULR N/A
- EPS
- DSGN N/A
- KULR N/A
- Revenue
- DSGN N/A
- KULR $11,436,983.00
- Revenue This Year
- DSGN N/A
- KULR $87.77
- Revenue Next Year
- DSGN N/A
- KULR $102.93
- P/E Ratio
- DSGN N/A
- KULR N/A
- Revenue Growth
- DSGN N/A
- KULR 16.47
- 52 Week Low
- DSGN $2.60
- KULR $1.60
- 52 Week High
- DSGN $7.77
- KULR $43.92
- Technical
- Relative Strength Index (RSI)
- DSGN 47.12
- KULR 36.93
- Support Level
- DSGN $3.89
- KULR $6.46
- Resistance Level
- DSGN $4.19
- KULR $6.98
- Average True Range (ATR)
- DSGN 0.23
- KULR 0.44
- MACD
- DSGN -0.02
- KULR -0.03
- Stochastic Oscillator
- DSGN 16.18
- KULR 6.13
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.
About KULR KULR Technology Group Inc.
KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices.